UroGen Pharma Ltd.
UGN-501
high-grade non-muscle invasive bladder cancer (HG-NMIBC)
Countdown
177days
Phase 1 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 1 trial results for UGN-501 in high-grade non-muscle invasive bladder cancer (HG-NMIBC) are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Investigational New Drug (IND)-enabling studies are nearing completion, and UroGen plans to submit an IND in the second quarter of 2026 and initiate a Phase 1 clinical trial in NMIBC by year end.”